Obstructive Sleep Apnea. A disorder characterized by cessation of breathing for short periods during sleep
Conditions
Interventions
Sponsors
Vice chancellor for research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
14 Years to 85 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria consist of adult patients with OSA and clinical indication for PAP therapy. Exclusion criteria consist of pregnancy, cardiopulmonary disorder, upper airway cancer or surgery, change or new administration of drug for hyperlipidemia, hypertension and diabetes mellitus.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: Sphygomanometer.;High density lipoprotein. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: Direct Enzymatic Colorimetric Method.;Fasting blood sugar. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: glucose oxidase assay.;Triglyceride. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: lipase peroxidase colorometric.;Abdominal Circumference. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: Metre. | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: scale.;Body Mass Index. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: scale and stadiometer.;C reactive protein. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: quantitative latex immunoturbidimetric assay.;Erythrocyte sedimentation rate. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: the Westergren method (therma).;Alkaline phosphatase. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: nitrophenyl phosphate kinetic.;Complete blood count. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: cell counter.;Hemoglobin A1c. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: High Performance Liquid Chromatography.;Alanine amino transferase. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: NADH Kinetic UV.;Aspartate amino tranferase. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: NADH Kinetic UV.;Uric acid. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: enzymatic colorimetric.;Cholesterol. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: cholestrol oxidase peroxidase colorimetric.;25 hydroxy vitamin D3. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: High Performance Liquid Chromatography.;Creatinine. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: jaffe kinetic colorimetric.;Blood urea nitrogen. Timepoint: before treatment and 3 month | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Mehraban
Tehran University of Medical Sciences
Outcome results
None listed